SI
SI
discoversearch

Biotech / Medical
Gilead Science (GILD) Followers
An SI Board Since March 1996
Posts SubjectMarks Bans Symbol
932 88 0 GILD
Emcee:  SybilNicolas Type:  Unmoderated
Any one offer insight about the potential of GILD? It just has an AIDS drug approved by FDA.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
932I've never sold juno, and don't remember if I ever held kite. Wasn'scaram(o)uche-12/14/2017
931Makes me start looking at Juno again. If GILD & NVS end up doing the heavy tuck-12/14/2017
930Five??? I expected issues. But five? Ugh.scaram(o)uche-12/14/2017
929Speaking of Kite, GILD's Yescarta likely to miss early estimates due to reimtuck-12/14/2017
928businesswire.com Gilead buys Cell Design Labs, adding to Kite focus (car-T).scaram(o)uche-12/7/2017
927So Anthem is restricting reimbursement of axicabtagene to patients who meet the tuck-11/9/2017
926i try to follow jacob's missives too, but i agree that was pretty weak analymopgcw-8/30/2017
925EPVantage with a pretty levelheaded take on the pros and cons of the KITE buyouttuck-8/30/2017
924On watch for clear above 67.14. [graphic]hollyhunter-6/5/2017
923Well, I am also holding for now, due to coming Bictegravir P3 data, May-end/midMiljenko Zuanic-5/16/2017
922fwiw, I am still holding for the long haul. if it dips to $60, i will add sharemopgcw-5/15/2017
921From WP article: <Through its Medicaid program, Louisiana covered Sovaldi andMiljenko Zuanic15/11/2017
920 gilead & U.S. Code Section 1498: a cautionary tale perhaps? washingtonsoftware salesperson-5/11/2017
919I have no idea what to do with my, relative large, GILD holding? Sell it with loMiljenko Zuanic-5/11/2017
918That priority review voucher could come in handy should they buy a late stage drmore100-2/22/2017
917This stock is giving me flashbacks to when I owned CVX. No one made $$ panic selmore10012/15/2017
916This week we find out if we are going to the 50s or 80s all eyes on HIV. Needs tmore100-2/13/2017
915I concur. the price issue may be sidetracked briefly, but it will not go away. mopgcw-11/9/2016
914Regardless failure of Pro 61 (and today broad bios gain), I do think and believeMiljenko Zuanic-11/9/2016
913REGN too, next year growth will decline...so whole SECTOR (more or less) is at PMiljenko Zuanic111/2/2016
912i conur. they are at a pivot point and the internal allocation of capital needsmopgcw-11/2/2016
911GILD in TROUBLE? It is obvious that to survive (as entity) GILD need to expand Miljenko Zuanic-11/1/2016
910Why not? Waste another 2 years for P2b? IF works...works! If not....did not loseMiljenko Zuanic-10/20/2016
909If we knew the answer, we would probably know why AGN paid a 500% premium to acqDewDiligence_on_SI-10/20/2016
908I know i am science limited, but why are they moving the NASH to p3? mopgcw-10/20/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.